Multiple Myeloma Symptoms Are Generally Nonspecific
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 19, 2023 -- Multiple myeloma (MM) symptoms are generally nonspecific, according to a study published online June 25 in Cancers.
Stella Bowcock, M.D., from the King's College Hospital NHS Trust in the United Kingdom, and colleagues explored the presenting symptoms to identify early signs of MM and their association with organ damage. Symptoms were recorded in the patients' own words at diagnosis. Patients who were seen by a hematologist more than six months before MM diagnoses were categorized as having precursor disease (PD). Data were provided by 962 of 977 patients.
The researchers found that the predominant symptoms were back pain, other pain, and systemic symptoms (38, 31, and 28 percent, respectively). Bone pain was rarely a complaint, but pain was. Vertebral fractures were underrecognized as pathological and were the predominant cause of irreversible organ damage (27 percent of patients), affecting performance status (PS) and associated with back pain, bone disease, and age older than 65 years (odds ratios, 6.14, 3.71, and 1.58, respectively). Renal failure occurred less often and was associated with gastrointestinal symptoms, age older than 65 years, and absence of back pain (odds ratios, 2.23, 2.14, and 0.44, respectively). Fewer vertebral fractures, fewer adverse features, less decline in PS, and a lower stage were seen for the 149 patients with known PD versus the 813 with de novo MM.
"Myeloma symptoms are nonspecific, and therefore, a long diagnostic pathway is likely to continue if we rely upon health care workers to think of the diagnosis before a myeloma screen is performed," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Persistent Sociodemographic Differences Seen in Use of AutoHCT for Multiple Myeloma
WEDNESDAY, May 8, 2024 -- Sociodemographic differences persist in utilization of autologous hematopoietic cell transplantation (autoHCT) for multiple myeloma, according to a study...
Self-Administered Acupressure Reduces Knee Pain With Suspected Osteoarthritis
WEDNESDAY, April 24, 2024 -- Self-administered acupressure (SAA) is an efficacious and cost-effective approach to relieve knee pain in middle-aged and older adults with probable...
FDA Approves Abecma for Relapsed, Refractory Multiple Myeloma
TUESDAY, April 9, 2024 -- The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.